The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions.
The center focuses specifically on treating individuals suffering from major depression disorder, bipolar disorder, post-traumatic stress disorder and obsessive compulsive disorder as their primary diagnosis.
Herein, this retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.
Compound Ketamine
Country Canada
Visit trial
Status
Enrolling by invitation
Results Published
Yes
Start date
03 December 2019
End date
01 December 2021
Chance of happening
100%
Design
Open
Type
Observational
Generation
First
Participants
260
Sex
All
Age
18- 65
Therapy
No
Trial Details
The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions. The center focuses specifically on treating individuals suffering from major depression disorder, bipolar disorder, post-traumatic stress disorder and obsessive compulsive disorder as their primary diagnosis. Herein, this retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.NCT Number NCT04209296
Sponsors & Collaborators
Brain and Cognition Discovery FoundationThis company doesn't have a full profile yet, it is linked to a clinical trial.
Papers
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youthThis retrospective analysis (n=52) investigates the efficacy of ketamine (35-52mg/70kg; 4x) for treating treatment-resistant depression (TRD) in transitional age youth (TAY; age 18-25), comparing them with matched adults. The study finds significant reductions in depression, anxiety, and suicidal ideation in the TAY group, with effect sizes indicative of clinically meaningful improvements. The benefits and safety outcomes in the TAY group were comparable to the GA group, suggesting ketamine can be equally effective and well-tolerated in younger patients with TRD.
Real World Effectiveness of Repeated Ketamine Infusions for Treatment Resistant Bipolar Depression
This real-world study (n=66) assessed the effects of four sub-anaesthetic doses of intravenous ketamine (35-52.5 mg/70kg) in participants with bipolar depression. Significant antidepressant effects were measured using the QIDS-SR, and further reductions were observed following each subsequent infusion. The rate of remission was 20% after all infusions.
Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder
This retrospective analysis (n=100) of the effectiveness of ketamine (35mg/70kg) for borderline personality disorder (BPD) in those with treatment-resistant depression (TRD) finds that intravenous ketamine significantly reduces symptoms of depression, borderline personality, suicidality, and anxiety in patients with comorbid BPD and TRD. Both BPD-positive and BPD-negative groups showed significant improvements in the primary outcome measures, with no significant difference between groups.
Measures Used
Quick Inventory of Depressive SymptomatologyThe Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR16) is a self-report tool designed to screen for depression and measure changes in the severity of symptoms.
Sheehan Disability Scale
The Sheehan Disability Scale (SDS) is a brief self-report measure developed to assess impairment in three inter-related domains; work/school, social life and family life.
Clinical-Administered Dissociative Symptoms Scale
The Clinical-Administered Dissociative Symptoms Scale (CADSS) is a scale used to measure dissociative states such as those induced by ketamine.